Measurement of fibroblast proliferative activity in bronchoalveolar lavage fluid in the analysis of obliterative bronchiolitis among lung transplant recipients

Journal of Heart and Lung Transplantation

Volumn 18, Issue 10, 1999, Pages 972-985

  Jonosono, Manabu ^a   Fang, Kenneth C ^a,b   Keith, Fraser M ^a   Turck, Christoph W ^a,b   Blanc, Paul D ^a,b   Hall, Timothy S ^a   Fukano, Anne K ^a   Rifkin, Celia J ^a   Gold, Warren M ^a,b   Webb, W Richard ^b   Edinburgh, Keith J ^b   Finkbeiner, Walter E ^a   Golden, Jeffrey A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRONCHIOLITIS; BRONCHOSCOPY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG BIOPSY; LUNG FIBROBLAST; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TRANSPLANTATION; MALE; PRIORITY JOURNAL; SPIROMETRY;

EID: 0032721250     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(99)00055-8     Document Type: Article

References (47)

1. Dauber J.H. Posttransplant bronchiolitis obliterans syndrome where have we been and where are we going? Chest. 109:(4):1996;857-859.
2. Reichenspurner H., Girgis R.E., Robbins R.C., et al. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg. 62:1996;1467-1473.
3. Scott J.P., Peters S.G., McDougall J.C., Beck K.C., Midthun D.E. Posttransplantation physiologic features of the lung and obliterative bronchiolitis. Mayo Clin Proc. 72:1997;170-174.
4. Paradis I., Yousem S., Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clin Chest Med. 14:(4):1993;751-763.
5. Ross D.J., Jordan S.C., Nathan S.D., Kass R.M., Koerner S.K. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation a plea for multicenter immunosuppressive trials . Chest. 109:1996;870-873.
6. Sundaresan S., Trulock E.P., Mohanakumar T., Cooper J.D., Patterson G.A. Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Ann Thorac Surg. 60:1995;1341-1347.
7. Kelly K., Hertz M.I. Obliterative Bronchiolitis. Clin Chest Med. 18:(2):1997;319-338.
8. Cooper J.D., Patterson G.A., Trulock E.P. Results of single and bilateral lung transplantation in 131 consecutive recipients. J Thorac Cardiovasc Surg. 107:1994;460-470.
9. Valentine V.G., Robbins R.C., Berry G.J., et al. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant. 15:1996;371-383.
10. Sharples L.D., Tamm M., McNeil K., Higenbottam T.W., Stewart S., Wallwork J. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation - early risk factors. Transplantation. 61:(4):1996;560-566.
11. Sundaresan S., Mohanakumar T., Smith M.A., et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation. 65:(5):1998;648-653.
12. Conte J.E. Jr, Golden J.A., Duncan S., McKenna E., Zurlinden E. Intrapulmonary pharmacokinetics of clarithroymcin and of erythromycin. Antimicrob Agents Chemother. 39:(2):1995;334-338.
13. Conte J.E. Jr, Golden J., Duncan S., McKenna E., Lin E., Zurlinden E. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother. 40:(7):1996;1617-1622.
14. DiGiovine B., Lynch J.P. III, Martinez F.J., et al. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation role of IL-8 . J Immunol. 157:1996;4194-4202.
15. Hertz M.I., Henke C.A., Nakhleh R.E., et al. Obliterative bronchiolitis after lung transplantation a fibroproliferative disorder associated with platelet-derived growth factor . Proc Natl Acad Sci USA. 89:1992;10385-10389.
16. Al-Dossari G.A., Jessurun J., Bolman R.M. III, et al. Pathogenesis of obliterative bronchiolitis. Transplantation. 59:(1):1995;143-145.
17. Magnan A., Mege J.L., Escallier J.C., et al. Balance between alveolar macrophage IL-6 and TGF-beta in lung-transplant recipients. Am J Respir Crit Care Med. 153:1996;1431-1436.
18. Adolff C.A., Golden J.A., Gamsu G., Goetzl E.J., Turck C.W. Reduction in pulmonary fibroblast-stimulating activity as an index of response to treatment of interstitial lung diseases. N Engl J Med. 322:(6):1990;1890-1891.
19. Kee S.T., Chen D., Webb W.R., Gamsu G., Finkbinder W., Golden J. Accuracy of high-resolution CT in diagnosing acute lung transplant rejection. Radiology. 197:(P):1995;438.
20. Blanc P.D., Golden J.A., Gamsu G., Aberle D.R., Gold W.M. Asbestos exposure - cigarette smoking interactions among shipyard workers. J Am Med Assoc. 259:(3):1988;370-373.
21. Golden J.A., Hollander H., Stulbarg M.S., Gamsu G. Bronchoalveolar lavage as the exclusive diagnostic modality for pneumocysitis carinii pneumonia, a prospective study among patients with acquired immunodeficiency syndrome. Chest. 90:1986;18-22.
22. Yang C.F., Wu M.T., Chiang A.A., et al. Correlation of high-resolution CT and pulmonary function in bronchiolitis obliterans a study based on 24 patients associated with consumption of Sauropus Androgynus . Am J Roentgenol. 168:1997;1045-1050.
23. Arakawa H., Webb W.R., McCowin M., Katsou G., Lee K.N., Seitz R.F. Inhomogeneous lung attenuation at thin-section CT diagnostic value of expiratory scans . Radiology. 206:(1):1998;89-94.
24. Stern E.J., Webb W.R., Gamsu G. Dynamic quantitative computed tomography a predictor or pulmonary function in obstructive lung diseases . Invest Radiol. 29:1994;564-569.
25. Stern E.J., Webb W.R. Dynamic imaging of lung morphology with ultrafast high-resolution computed tomography. J Thorac Imaging. 8:1993;273-282.
26. Lucidarme O, Coche E, Cluzel P, Mourey-Gerosa I, Howarth N, Grenier P. Expiratory CT scans for chronic airway disease: correlation with pulmonary function test results. 1998;170:301-7.
27. Willcox M., Kervitsky A., Watters L.C., King T.E. Jr. Quantification of cells recovered by bronchoalveolar lavage comparison of cytocentrifuge preparations with the filter method . Am Rev Respir Dis. 138:1988;74-80.
28. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection lung rejection study group . J Heart Lung Transplant. 15:1996;1-15.
29. Cooper J.D., Billingham M., Egan T., et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant. 12:1993;713-716.
30. Patterson G.M., Wilson S., Whang J.L., et al. Physiologic definitions of obliterative bronchiolitis in heart-lung and double lung transplantation a comparison of the forced expiratory flow between 25% and 75% of the forced vital capacity and forced expiratory volume in one second . J Heart Lung Transplant. 15:(2):1996;175-181.
31. Hilal S.E., Keith F.M., Golden J.A., Gold W.M. Correlation between volume corrected flow and complications in single lung transplant. Am J Respir Crit Care Med. 155:(4):1997;A383.
32. Tani K., Yasuoka S., Ogushi F., et al. Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 5:1991;34-40.
33. Williams T.J., Grossman R.F., Maurer J.R. Long-term functional follow-up of lung transplant recipients. Clin Chest Med. 11:(2):1990;347-358.
34. Magnan A., Mege J.L., Reynaud M., et al. Monitoring of alveolar macrophage production of tumor necrosis factor-alpha and interleukin-6 in lung transplant recipients. Am J Respir Crit Care Med. 150:1994;684-689.
35. Bando K., Paradis I.L., Similo S., et al. Obliterative bronchiolitis after lung and heart-lung transplantation an analysis of risk factors and management . J Thorac Cardiovasc Surg. 110:1995;4-14.
36. Siddiqui M.T., Garrity E.R., Martinez R., Husain A.N. Bronchiolar basement membrane changes and bronchiolitis obliterans in lung allografts study. Mod Pathol. 9:(3):1996;320-328.
37. Girgis R.E., Tu I., Berry G.J., et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant. 15:1996;1200-1208.
38. Yousem S.A. Significance of clinically silent untreated mild acute cellular rejection in lung allograft recipients. Hum Pathol. 27:1996;269-273.
39. Kroshus T.J., Kshettry V.R., Savik K., et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg. 114:1997;195-202.
40. Winter J.B., Gouw A.S., Groen M., Wildevuur C., Prop J. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation. 57:(3):1994;418-422.
41. Rizzo M., Sundaresan S., Lynch J., et al. Increased concentration of soluble human leukocyte antigen class I levels in the bronchoalveolar lavage of human pulmonary allografts. J Heart Lung Transplant. 16:1997;1135-1140.
42. Mauck K.A., Hosenpud J.D. The bronchial epithelium a potential allogeneic target for chronic rejection after lung transplantation . J Heart Lung Transplant. 15:1996;709-714.
43. Lee A.G.L., Wagner F.M., Chen M.-F., Serrick C., Giaid A., Shennib H. A novel charcoal-induced model of obliterative bronchiolitis-like lesions implications of chronic nonspecific airway inflammation in the development of posttransplantation obliterative bronchiolitis . J Thorac Cardiovasc Surg. 115:1998;822-827.
44. Hertz M.I., Jessurun J., King M.B., et al. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol. 142:1993;1945-1951.
45. Molossi S., Elices M., Arrhenius T., Diaz R., Coulber C., Rabinovitch M. Blockade of very late antigen-4 integrin binding of fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy. J Clin Invest. 95:1995;2610.
46. Akselband Y., Harding M.W., Nelson P.A. Rapamycin inhibits spontaneous and fibroblast growth factor b-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc. 23:1991;2833-2836.
47. Gregory C.R., Huie P., Billingham M.E., Morris R.E. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor and cytokine response in injured vessels. Transplantation. 55:1993;1409-1418.